Phosphorylation status of matrix metalloproteinase 2 in myocardial ischaemia - Reperfusion injury

Heart

Volumn 98, Issue 8, 2012, Pages 656-662

  Sariahmetoglu, Meltem ^a   Skrzypiec Spring, Monika ^b   Youssef, Nermeen ^a   Jacob Ferreira, Anna Laura B ^a   Sawicka, Jolanta ^c   Holmes, Charles ^a   Sawicki, Grzegorz ^b,c   Schulz, Richard ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; PHOSPHOPROTEIN PHOSPHATASE 2A; TROPONIN I;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; ENZYME RELEASE; HEART MUSCLE ISCHEMIA; IMMUNOPRECIPITATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; RAT; REPERFUSION INJURY; SPRAGUE DAWLEY RAT;

ALKALINE PHOSPHATASE; ANIMALS; ENZYME INHIBITORS; HEART; MALE; MATRIX METALLOPROTEINASE 2; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; OKADAIC ACID; PHOSPHORYLATION; PROTEIN PHOSPHATASE 1; PROTEIN PHOSPHATASE 2; RATS; RATS, SPRAGUE-DAWLEY; TROPONIN I;

EID: 84860167123     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2011-301250     Document Type: Article

References (33)

1. Cheung PY, Sawicki G, Wozniak M, et al. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000;101:1833-9. (Pubitemid 30213106)
2. Wang W, Sawicki G, Schulz R. Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res 2002;53:165-74. (Pubitemid 34020777)
3. Gao CQ, Sawicki G, Suarez-Pinzon WL, et al. Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. Cardiovasc Res 2003;57:426-33. (Pubitemid 36144221)
4. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 2007;47:211-42.
5. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69:562-73. (Pubitemid 43139720)
6. Wang W, Schulze CJ, Suarez-Pinzon WL, et al. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002;106:1543-9.
7. Sawicki G, Leon H, Sawicka J, et al. Degradation of myosin light chain in isolated rat hearts subjected to ischemia - reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation 2005;112:544-52. (Pubitemid 41060795)
8. Sung MM, Schulz CG, Wang W, et al. Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury. J Mol Cell Cardiol 2007;43:429-36. (Pubitemid 47451426)
9. Ali MA, Cho WJ, Hudson B, et al. Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury. Circulation 2010;122:2039-47.
10. Ishihara H, Martin BL, Brautigan DL, et al. Calyculin A and okadaic acid: inhibitors of protein phosphatase activity. Biochem Biophys Res Commun 1989;159:871-7. (Pubitemid 19101063)
11. Wera S, Hemmings BA. Serine/threonine protein phosphatases. Biochem J 1995;311:17-29.
12. Dawson JF, Holmes CF. Molecular mechanisms underlying inhibition of protein phosphatases by marine toxins. Front Biosci 1999;4:D646-58.
13. Gupta RC, Neumann J, Watanabe AM, et al. Evidence for presence and hormonal regulation of protein phosphatase inhibitor-1 in ventricular cardiomyocyte. Am J Physiol 1996;270:H1159-64.
14. Luss H, Klein-Wiele O, Boknik P, et al. Regional expression of protein phosphatase type 1 and 2A catalytic subunit isoforms in the human heart. J Mol Cell Cardiol 2000;32:2349-59. (Pubitemid 32042138)
15. Sariahmetoglu M, Crawford BD, Leon H, et al. Regulation of matrix metalloproteinase-2 (MMP-2) activity by phosphorylation. FASEB J 2007;21:2486-95. (Pubitemid 47230678)
16. Nyalendo C, Michaud M, Beaulieu E, et al. Src-dependent phosphorylation of membrane type I matrix metalloproteinase on cytoplasmic tyrosine 573: role in endothelial and tumor cell migration. J Biol Chem 2007;282:15690-9. (Pubitemid 47093303)
17. Nyalendo C, Beaulieu E, Sartelet H, et al. Impaired tyrosine phosphorylation of membrane type 1-matrix metalloproteinase reduces tumor cell proliferation in three-dimensional matrices and abrogates tumor growth in mice. Carcinogenesis 2008;29:1655-64.
18. Kobryn CE, Mandel LJ. Decreased protein phosphorylation induced by anoxia in proximal renal tubules. Am J Physiol 1994;267:C1073-9.
19. Blom N, Gammeltoft S, Brunak S. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J Mol Biol 1999;294:1351-62. (Pubitemid 30008805)
20. Sawicki G, Salas E, Murat J, et al. Release of gelatinase A during platelet activation mediates aggregation. Nature 1997;386:616-19. (Pubitemid 27175428)
21. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
22. Ferry G, Lonchampt M, Pennel L, et al. Activation of MMP-9 by neutrophil elastase in an in vivo model of acute lung injury. FEBS Lett 1997;402:111-15. (Pubitemid 27078240)
23. Bergman MR, Teerlink JR, Mahimkar R, et al. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol 2007;292:H1847-60. (Pubitemid 46572408)
24. Fernandez JJ, Candenas ML, Souto ML, et al. Okadaic acid, useful tool for studying cellular processes. Curr Med Chem 2002;9:229-62. (Pubitemid 34436443)
25. Neumann J, Boknik P, Herzig S, et al. Evidence for physiological functions of protein phosphatases in the heart: evaluation with okadaic acid. Am J Physiol 1993;265:H257-66. (Pubitemid 23224719)
26. Armstrong SC, Ganote CE. Effects of the protein phosphatase inhibitors okadaic acid and calyculin A on metabolically inhibited and ischaemic isolated myocytes. J Mol Cell Cardiol 1992;24:869-84.
27. Armstrong SC, Gao W, Lane JR, et al. Protein phosphatase inhibitors calyculin A and fostriecin protect rabbit cardiomyocytes in late ischemia. J Mol Cell Cardiol 1998;30:61-73. (Pubitemid 28069745)
28. Armstrong SC, Hoover DB, Delacey MH, et al. Translocation of PKC, protein phosphatase inhibition and preconditioning of rabbit cardiomyocytes. J Mol Cell Cardiol 1996;28:1479-92. (Pubitemid 26340902)
29. Fenton RA, Dickson EW, Dobson JG Jr. Inhibition of phosphatase activity enhances preconditioning and limits cell death in the ischemic/reperfused aged rat heart. Life Sci 2005;77:3375-88. (Pubitemid 41434080)
30. Weinbrenner C, Baines CP, Liu GS, et al. Fostriecin, an inhibitor of protein phosphatase 2A, limits myocardial infarct size even when administered after onset of ischemia. Circulation 1998;98:899-905. (Pubitemid 28397440)
31. Ingebritsen TS, Stewart AA, Cohen P. The protein phosphatases involved in cellular regulation. 6. Measurement of type-1 and type-2 protein phosphatases in extracts of mammalian tissues; an assessment of their physiological roles. Eur J Biochem 1983;132:297-307. (Pubitemid 13093427)
32. Skrzypiec-Spring M, Grotthus B, Szelag A, et al. Isolated heart perfusion according to Langendorff - still viable in the new millennium. J Pharmacol Toxicol Methods 2007;55:113-26. (Pubitemid 46227990)
33. Jordan JE, Zhao ZQ, Vinten-Johansen J. The role of neutrophils in myocardial ischemia - reperfusion injury. Cardiovasc Res 1999;43:860-78. (Pubitemid 29413185)